FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability.

@article{Silswal2014FGF23DI,
  title={FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability.},
  author={Neerupma Silswal and Chad D. Touchberry and Dorothy R Daniel and Darla L McCarthy and Shiqin Zhang and Jon Andresen and Jason R. Stubbs and Michael J. Wacker},
  journal={American journal of physiology. Endocrinology and metabolism},
  year={2014},
  volume={307 5},
  pages={E426-36}
}
Fibroblast growth factor 23 (FGF23) is secreted primarily by osteocytes and regulates phosphate and vitamin D metabolism. Elevated levels of FGF23 are clinically associated with endothelial dysfunction and arterial stiffness in chronic kidney disease (CKD) patients; however, the direct effects of FGF23 on endothelial function are unknown. We hypothesized that FGF23 directly impairs endothelial vasorelaxation by hindering nitric oxide (NO) bioavailability. We detected expression of all four… CONTINUE READING